The final results of the interferon beta-1b 16-year long-term follow-up study

The final results of the interferon beta-1b 16-year long-term follow-up study

Detalhes bibliográficos
Principais autores:	Ebers, G, Traboulsee, A, Langdon, D, Reder, A, Miltenburger, C, Wolf, C, Konieczny, A
Formato:	Conference item
Publicado em:	2006

Registros relacionados

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
por: Ebers, G, et al.
Publicado em: (2009)

The interferon beta-1b 16-year long-term follow-up study: Neutralizing antibodies and clinical outcomes
por: Reder, A, et al.
Publicado em: (2008)

16-year long-term follow-up of interferon beta-1b treatment in patients with multiple sclerosis
por: Ebers, G, et al.
Publicado em: (2005)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
por: Goodin, D, et al.
Publicado em: (2012)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
por: Goodin, D, et al.
Publicado em: (2012)

Long-term follow up of interferon-beta-1b pivotal trial RRMS patients: design issues of a 16-year follow-up study
por: Ebers, G, et al.
Publicado em: (2004)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
por: Goodin, D, et al.
Publicado em: (2012)

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
por: Reder, A, et al.
Publicado em: (2010)

EDSS and MRI burden of disease predict cognitive status at 16 years: data from the long term follow-up study
por: Langdon, D, et al.
Publicado em: (2007)

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
por: Ebers, G, et al.
Publicado em: (2010)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
por: Sibley, W, et al.
Publicado em: (1994)

Treatment of multiple sclerosis with interferon beta-1b - Reply
por: Sibley, W, et al.
Publicado em: (1997)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
por: Petkau, A, et al.
Publicado em: (2004)

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
por: Bernard Uitdehaag, et al.
Publicado em: (2011-01-01)

Experiences with interferon-beta-1b treatment in MS after three year follow-up
por: T Járdánházy, et al.
Publicado em: (2002-05-01)

INTERFERON BETA-1B IN THE TREATMENT OF MULTIPLE-SCLEROSIS - FINAL OUTCOME OF THE RANDOMIZED CONTROLLED TRIAL
por: Duquette, P, et al.
Publicado em: (1995)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
por: Megen C. Wittling, et al.
Publicado em: (2021-01-01)

Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
por: Rice, G, et al.
Publicado em: (1999)

Randomized controlled trial of interferon-beta-1a in secondary progressive MS - Clinical results
por: King, J, et al.
Publicado em: (2001)

CAUSE OF DEATH IN MULTIPLE SCLEROSIS PATIENTS FROM THE 21-YEAR LONG-TERM FOLLOW-UP STUDY
por: Ebers, G, et al.
Publicado em: (2011)

Treatment of Chronic Hepatitis B with Interferon: Long Term Follow-Up
por: Jean-Pierre Villeneuve, et al.
Publicado em: (1996-01-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
por: Petkau, A, et al.
Publicado em: (2004)

Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon
por: Jane D Collier, et al.
Publicado em: (2000-01-01)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Shannon Kolind, et al.
Publicado em: (2022-01-01)

Beta-interferons in multiple sclerosis
por: Aggarwal Sourabh, et al.
Publicado em: (2010-01-01)

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
por: Mark S. Freedman, et al.
Publicado em: (2024-01-01)

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
por: Francis, G, et al.
Publicado em: (2001)

Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma
por: Morris Cindy A, et al.
Publicado em: (2005-02-01)

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
por: Emmanuel Bachy, et al.
Publicado em: (2013-07-01)

Treatment of multiple sclerosis with interferon beta-1 b.
por: Abdul-Ahad, A, et al.
Publicado em: (1997)

Thrombotic microangiopathy associated with use of interferon-beta
por: Robles A, et al.
Publicado em: (2012-06-01)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis (vol 352, pg 1498, 1998)
por: Ebers, G, et al.
Publicado em: (1999)

Interferon beta treatment of multiple sclerosis.
por: Markovitz, D
Publicado em: (1994)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
por: Mohamed Rayen Ganouni, et al.
Publicado em: (2023-10-01)

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
por: Goodin, D, et al.
Publicado em: (2012)

Analysis of the competitive load in u16 handballers as a function of the final result
por: David Mancha Triguero, et al.
Publicado em: (2018-10-01)

Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy
por: C. Carbonelli, et al.
Publicado em: (2015-12-01)

Systemic interferon alfa in multiple sclerosis.
por: Weinshenker, BG, et al.
Publicado em: (1989)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
por: Sørensen, P, et al.
Publicado em: (2010)

Efficacy and safety of the new drug against multiple sclerosis «PEGylated Interferon beta-1a Human» in monkeys compared with unmodified interferon beta-1a
por: N. A. Spirina, et al.
Publicado em: (2018-02-01)